Worth reading
72In focus
Scored from 2 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
5894
¥ millionWording
Definitive
How definitive the wording is.Contents of this document
Earnings presentationNine months ended September 2026 (January–September)3 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥27,742 million
Operating profit¥3,175 million
Net income¥2,328 million
Selling, general and administrative expenses¥8,333 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in the number of milestones achieved
- Increase in product revenue
- Decrease in R&D expenses¥2,237 million
- Decrease in selling, general and administrative expenses¥1,023 million
New initiatives
- Exclusive licensing, supply and commercialization agreement with Synmosa Biopharma Corporation for QUVIVIQ® in 8 Asia-Pacific markets
- Marketing authorization application for vamorolone in South Korea
- Exercise of the option to obtain a license for lucerastat and co-development and commercialization agreement with Idorsia
- Licensing agreement concerning a GPCR-targeted program with a newly established venture and participation in its Series A financing
Key KPIsA metric the company considers important as a management benchmark.
- Number of milestones achieved10 EngagementsYear on year against the same period last yearIncreased from 6 in the same period of the previous year
- Number of pipeline programsMore than 30
- Cash and cash equivalents¥16,613 millionYear on year against the same period last yearDecreased by ¥3,752 million from the end of the previous consolidated fiscal year
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Nine months ended September 2026 (January–September) |
| Net Sales | ¥27,742 million |
| Operating profit | ¥3,175 million |
| Net income | ¥2,328 million |
| Selling, general and administrative expenses | ¥8,333 million |
| Breakdown of Factors Affecting the Change | Factors Increase in the number of milestones achieved / Amount Not disclosed, Factors Increase in product revenue / Amount Not disclosed, Factors Decrease in R&D expenses / Amount ¥2,237 million, Factors Decrease in selling, general and administrative expenses / Amount ¥1,023 million |
| Key KPIs | Indicator name Number of milestones achieved / Value 10 Engagements / Year on year against the same period last year Increased from 6 in the same period of the previous year, Indicator name Number of pipeline programs / Value More than 30 / Year on year against the same period last year Not disclosed, Indicator name Cash and cash equivalents / Value ¥16,613 million / Year on year against the same period last year Decreased by ¥3,752 million from the end of the previous consolidated fiscal year |
| New initiatives | Exclusive licensing, supply and commercialization agreement with Synmosa Biopharma Corporation for QUVIVIQ® in 8 Asia-Pacific markets, Marketing authorization application for vamorolone in South Korea, Exercise of the option to obtain a license for lucerastat and co-development and commercialization agreement with Idorsia, Licensing agreement concerning a GPCR-targeted program with a newly established venture and participation in its Series A financing |
Items this document does not state (22)
Ordinary incomeGross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue was attributable to the number of milestones achieved rising from 6 in the same period of the previous year to 10, as well as product revenue exceeding that of the same period of the previous year. Research and development expenses decreased due to lower costs accompanying progress in multiple clinical development programs and a greater focus on research and development areas, while selling, general and administrative expenses decreased as a result of cost-reduction initiatives.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.